Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 20

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Emerging insights into ethnic-specific TP53 germline variants

Fischer, Nicholas W, Ma, Yu-Heng Vivian, Gariépy, Jean·2023·JNCI: Journal of the National Cancer Institute

Abstract

The recent expansion of human genomics repositories has facilitated the discovery of novel TP53 variants in populations of different ethnic origins. Interpreting TP53 variants is a major clinical challenge because they are functionally diverse, confer highly variable predisposition to cancer (including elusive low-penetrance alleles), and interact with genetic modifiers that alter tumor susceptibility. Here, we discuss how a cancer risk continuum may relate to germline TP53 mutations on the basis of our current review of genotype–phenotype studies and an integrative analysis combining functional and sequencing datasets. Our study reveals that each ancestry contains a distinct TP53 variant landscape defined by enriched ethnic-specific alleles. In particular, the discovery and characterization of suspected low-penetrance ethnic-specific variants with unique functional consequences, including P47S (African), G334R (Ashkenazi Jewish), and rs78378222 (Icelandic), may provide new insights in terms of managing cancer risk and the efficacy of therapy. Additionally, our analysis highlights infrequent variants linked to milder cancer phenotypes in various published reports that may be underdiagnosed and require further investigation, including D49H in East Asians and R181H in Europeans. Overall, the sequencing and projected functions of TP53 variants arising within ethnic populations and their interplay with modifiers, as well as the emergence of CRISPR screens and AI tools, are now rapidly improving our understanding of the cancer susceptibility spectrum, leading toward more accurate and personalized cancer risk assessments.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djad106

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 69

  1. Leroy, 2014, TP53 mutations in human cancer: database reassessment and prospects for the next decade, Hum Mutat, 35, 672, 10.1002/humu.22552 · DOI · Paper page
  2. Malkin, 1990, Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms, Science, 250, 1233, 10.1126/science.1978757 · DOI · Paper page
  3. Rogoża-Janiszewska, 2021, Prevalence of recurrent mutations predisposing to breast cancer in early-onset breast cancer patients from Poland, Breast Cancer, 28, 226, 10.1007/s12282-020-01151-7 · DOI
  4. McCuaig, 2012, Routine TP53 testing for breast cancer under age 30: ready for prime time?, Fam Cancer, 11, 607, 10.1007/s10689-012-9557-z · DOI
  5. Sheng, 2020, Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer, Int J Cancer, 146, 487, 10.1002/ijc.32424 · DOI
  6. Bakhuizen, 2019, TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort, Fam Cancer, 18, 273, 10.1007/s10689-018-00118-0 · DOI
  7. de Andrade, 2021, Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study, Lancet Oncol, 22, 1787, 10.1016/S1470-2045(21)00580-5 · DOI · Paper page
  8. Kratz, 2017, Cancer screening recommendations for individuals with Li-Fraumeni syndrome, Clin Cancer Res, 23, e38, 10.1158/1078-0432.CCR-17-0408 · DOI · Paper page
  9. de Andrade, 2017, Higher-than-expected population prevalence of potentially pathogenic germline TP53 variants in individuals unselected for cancer history, Hum Mutat, 38, 1723, 10.1002/humu.23320 · DOI
  10. de Andrade, 2022, The TP53 database: transition from the International Agency for Research on Cancer to the US National Cancer Institute, Cell Death Differ, 29, 1071, 10.1038/s41418-022-00976-3 · DOI · Paper page
  11. Karczewski, 2020, The mutational constraint spectrum quantified from variation in 141,456 humans, Nature, 581, 434, 10.1038/s41586-020-2308-7 · DOI · Paper page
  12. Hainaut, 2016, Somatic TP53 mutations in the era of genome sequencing, Cold Spring Harb Perspect Med, 6, a026179, 10.1101/cshperspect.a026179 · DOI · Paper page
  13. Kotler, 2018, A systematic p53 mutation library links differential functional impact to cancer mutation pattern and evolutionary conservation, Mol Cell, 71, 178, 10.1016/j.molcel.2018.06.012 · DOI · Paper page
  14. Hoyos, 2022, Fundamental immune-oncogenicity trade-offs define driver mutation fitness, Nature, 606, 172, 10.1038/s41586-022-04696-z · DOI
  15. Barnoud, 2019, Common genetic variants in the TP53 pathway and their impact on cancer, J Mol Cell Biol, 11, 578, 10.1093/jmcb/mjz052 · DOI
  16. Kato, 2003, Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis, Proc Natl Acad Sci USA., 100, 8424, 10.1073/pnas.1431692100 · DOI · Paper page
  17. Xu, 2011, Gain of function of mutant p53 by coaggregation with multiple tumor suppressors, Nat Chem Biol, 7, 285, 10.1038/nchembio.546 · DOI · Paper page
  18. Kratz, 2021, Analysis of the Li-Fraumeni spectrum based on an international germline TP53 variant data set: an international agency for research on cancer TP53 database analysis, JAMA Oncol, 7, 1800, 10.1001/jamaoncol.2021.4398 · DOI
  19. Fischer, 2018, Survival in males with glioma and gastric adenocarcinoma correlates with mutant p53 residual transcriptional activity, JCI Insight, 3, e121364, 10.1172/jci.insight.121364 · DOI
  20. Fischer, 2018, Association between the oligomeric status of p53 and clinical outcomes in Li-Fraumeni syndrome, J Natl Cancer Inst, 110, 1418, 10.1093/jnci/djy114 · DOI
  21. Xu, 2014, Heterogeneity of Li-Fraumeni syndrome links to unequal gain-of-function effects of p53 mutations, Sci Rep, 4, 4223, 10.1038/srep04223 · DOI
  22. Monti, 2007, Transcriptional functionality of germ line p53 mutants influences cancer phenotype, Clin Cancer Res, 13, 3789, 10.1158/1078-0432.CCR-06-2545 · DOI · Paper page
  23. Fischer, 2016, p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis, Cell Cycle, 15, 3210, 10.1080/15384101.2016.1241917 · DOI
  24. Gonzalez, 2009, Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations, J Clin Oncol, 27, 1250, 10.1200/JCO.2008.16.6959 · DOI · Paper page
  25. McBride, 2017, Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?, Fam Cancer, 16, 423, 10.1007/s10689-016-9964-7 · DOI
  26. Beckman, 1994, Is p53 polymorphism maintained by natural selection?, Hum Hered., 44, 266, 10.1159/000154228 · DOI · Paper page
  27. Shi, 2009, Winter temperature and UV are tightly linked to genetic changes in the p53 tumor suppressor pathway in Eastern Asia, Am J Hum Genet, 84, 534, 10.1016/j.ajhg.2009.03.009 · DOI
  28. Kung, 2016, The P72R polymorphism of p53 predisposes to obesity and metabolic dysfunction, Cell Rep, 14, 2413, 10.1016/j.celrep.2016.02.037 · DOI · Paper page
  29. Dumont, 2003, The codon 72 polymorphic variants of p53 have markedly different apoptotic potential, Nat Genet, 33, 357, 10.1038/ng1093 · DOI · Paper page
  30. Kung, 2017, The codon 72 polymorphism of p53 influences cell fate following nutrient deprivation, Cancer Biol Ther, 18, 484, 10.1080/15384047.2017.1323595 · DOI
  31. Whibley, 2009, p53 polymorphisms: cancer implications, Nat Rev Cancer, 9, 95, 10.1038/nrc2584 · DOI · Paper page
  32. Felley-Bosco, 1993, Functional studies of a germ-line polymorphism at codon 47 within the p53 gene, Am J Hum Genet, 53, 752
  33. Jennis, 2016, An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model, Genes Dev, 30, 918, 10.1101/gad.275891.115 · DOI · Paper page
  34. Murphy, 2017, A functionally significant SNP in TP53 and breast cancer risk in African-American women, NPJ Breast Cancer, 3, 5, 10.1038/s41523-017-0007-9 · DOI
  35. Li, 2005, Function of polo-like kinase 3 in NF-kappaB-mediated proapoptotic response, J Biol Chem, 280, 16843, 10.1074/jbc.M410119200 · DOI
  36. Barnoud, 2018, Tailoring chemotherapy for the African-Centric S47 variant of TP53, Cancer Res, 78, 5694, 10.1158/0008-5472.CAN-18-1327 · DOI
  37. Singh, 2020, African-centric TP53 variant increases iron accumulation and bacterial pathogenesis but improves response to malaria toxin, Nat Commun, 11, 473, 10.1038/s41467-019-14151-9 · DOI
  38. Gnanapradeepan, 2020, Increased mTOR activity and metabolic efficiency in mouse and human cells containing the African-centric tumor-predisposing p53 variant Pro47Ser, Elife, 9, e55994, 10.7554/eLife.55994 · DOI
  39. Macaulay, 2018, The first two confirmed sub-Saharan African families with germline TP53 mutations causing Li-Fraumeni syndrome, Fam Cancer, 17, 607, 10.1007/s10689-018-0075-5 · DOI
  40. Doffe, 2021, Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene, Cell Death Differ, 28, 1477, 10.1038/s41418-020-00672-0 · DOI
  41. Park, 2016, Germline TP53 mutation and clinical characteristics of Korean patients with Li-Fraumeni syndrome, Ann Lab Med, 36, 463, 10.3343/alm.2016.36.5.463 · DOI
  42. Yamaguchi, 2016, Prevalence of low-penetrant germline TP53 D49H mutation in Japanese cancer patients, Biomed Res, 37, 259, 10.2220/biomedres.37.259 · DOI
  43. Yamazaki, 2018, Nodular lymphocyte-predominant hodgkin lymphoma in a 15-year-old boy with Li-Fraumeni syndrome having a germline TP53 D49H mutation, J Pediatr Hematol Oncol, 40, e195, 10.1097/MPH.0000000000000948 · DOI
  44. Lee, 2010, Structure of the p53 transactivation domain in complex with the nuclear receptor coactivator binding domain of CREB binding protein, Biochemistry, 49, 9964, 10.1021/bi1012996 · DOI · Paper page
  45. Cho, 2013, A case of late-onset Li-Fraumeni-like syndrome with unilateral breast cancer, Ann Lab Med, 33, 212, 10.3343/alm.2013.33.3.212 · DOI
  46. Light, 2023, Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis, Nat Commun, 14, 77, 10.1038/s41467-022-35727-y · DOI
  47. Miyaki, 2003, A novel case with germline p53 gene mutation having concurrent multiple primary colon tumours, Gut, 52, 304, 10.1136/gut.52.2.304 · DOI
  48. Pinto, 2020, What 20 years of research has taught us about the TP53 p.R337H mutation, Cancer, 126, 4678, 10.1002/cncr.33143 · DOI · Paper page
  49. DiGiammarino, 2002, A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer, Nat Struct Biol, 9, 12, 10.1038/nsb730 · DOI · Paper page
  50. Wasserman, 2015, Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study, J Clin Oncol, 33, 602, 10.1200/JCO.2013.52.6863 · DOI · Paper page
  51. Pinto, 2020, XAF1 as a modifier of p53 function and cancer susceptibility, Sci Adv, 6, eaba3231, 10.1126/sciadv.aba3231 · DOI
  52. Park, 2018, Mouse homolog of the human TP53 R337H mutation reveals its role in tumorigenesis, Cancer Res, 78, 5375, 10.1158/0008-5472.CAN-18-0016 · DOI
  53. Jeffers, 2021, The common germline TP53-R337H mutation is hypomorphic and confers incomplete penetrance and late tumor onset in a mouse model, Cancer Res, 81, 2442, 10.1158/0008-5472.CAN-20-1750 · DOI
  54. Powers, 2020, A rare TP53 mutation predominant in Ashkenazi Jews confers risk of multiple cancers, Cancer Res, 80, 3732, 10.1158/0008-5472.CAN-20-1390 · DOI
  55. Stacey, 2011, Germline variant in the TP53 polyadenylation signal confers cancer susceptibility, Nat Genet, 43, 1098, 10.1038/ng.926 · DOI · Paper page
  56. Li, 2013, Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program, Blood, 121, 4529, 10.1182/blood-2012-12-471722 · DOI
  57. Egan, 2012, Rare TP53 genetic variant associated with glioma risk and outcome, J Med Genet, 49, 420, 10.1136/jmedgenet-2012-100941 · DOI
  58. Zhou, 2012, LMO4 inhibits p53-mediated proliferative inhibition of breast cancer cells through interacting p53, Life Sci, 91, 358, 10.1016/j.lfs.2012.08.005 · doi:10.1016/j.lfs.2012.08.005
  59. Enciso-Mora, 2013, Low penetrance susceptibility to glioma is caused by the TP53 variant rs78378222, Br J Cancer, 108, 2178, 10.1038/bjc.2013.155 · doi:10.1038/bjc.2013.155
  60. Diskin, 2014, Rare variants in TP53 and susceptibility to neuroblastoma, J Natl Cancer Inst, 106, dju047, 10.1093/jnci/dju047 · DOI
  61. Macedo, 2016, Rare germline variant (rs78378222) in the TP53 3' UTR: evidence for a new mechanism of cancer predisposition in Li-Fraumeni syndrome, Cancer Genet, 209, 97, 10.1016/j.cancergen.2015.12.012 · DOI
  62. Redman-Rivera, 2021, Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes, Nat Commun, 12, 5184, 10.1038/s41467-021-25359-z · DOI
  63. Erwood, 2022, Saturation variant interpretation using CRISPR prime editing, Nat Biotechnol, 40, 885, 10.1038/s41587-021-01201-1 · DOI · Paper page
  64. Raad, 2021, Blood functional assay for rapid clinical interpretation of germline TP53 variants, J Med Genet, 58, 796, 10.1136/jmedgenet-2020-107059 · DOI
  65. Zerdoumi, 2017, TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage, Hum Mol Genet, 26, 2812, 10.1093/hmg/ddx165 · DOI
  66. Leung, 2023, Common activities and predictive gene signature identified for genetic hypomorphs of TP53, Proc Natl Acad Sci USA., 120, e2212940120, 10.1073/pnas.2212940120 · DOI
  67. Noguchi, 2022, Artificial intelligence program to predict p53 mutations in ulcerative colitis-associated cancer or dysplasia, Inflamm Bowel Dis, 28, 1072, 10.1093/ibd/izab350 · DOI
  68. Ma, 2022, Artificial intelligence based study association between p53 gene polymorphism and endometriosis: a systematic review and meta-analysis, Comput Intell Neurosci, 2022, 8568820, 10.1155/2022/8568820 · DOI
  69. Ben-Cohen, 2022, TP53_PROF: a machine learning model to predict impact of missense mutations in TP53, Brief Bioinform, 23, bbab524, 10.1093/bib/bbab524 · DOI

Cited by

See all 20

Metadata

Authors
Fischer, N. W., Ma, Y.-H. V., & Gariépy, J.
Venue
JNCI: Journal of the National Cancer Institute
Published
2023-06-23
Volume
115
Issue
10
Pages
1145-1156
ISSN
  • 0027-8874
  • 1460-2105
Cited by
20
References
6
Language
en
Funders
Canadian Institutes of Health Research (125862, 148556)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Emerging insights into ethnic-specific TP53 germline variants. https://app.cochat.ai/papers/10.1093/jnci/djad106
The paper
Fischer, N. W., Ma, Y.-H. V., & Gariépy, J. (2023). Emerging insights into ethnic-specific TP53 germline variants. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djad106

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.